---
title: "Bio-Techne Corp Stock 12‑Month Price Target Raised to $66.42, Implies 13% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290871586.md"
description: "Bio-Techne Corp's average 12-month price target has been raised to $66.42 by 12 analysts, up from $65.33, implying a 13% upside based on the June 24 closing price. The consensus rating remains 'Buy' across 19 covering analysts, with forecasts ranging from $50 to $75 per share."
datetime: "2026-06-25T19:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290871586.md)
  - [en](https://longbridge.com/en/news/290871586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290871586.md)
---

# Bio-Techne Corp Stock 12‑Month Price Target Raised to $66.42, Implies 13% Upside

-   According to estimates from 12 analysts, Bio-Techne Corp stock's average price target has risen from $65.33 to $66.42, with forecasts ranging from $50 to $75 per share
-   Based on the Jun. 24 closing price, the updated target implies approximately 13% potential upside
-   Consensus rating remains at “Buy” across 19 covering analysts, with 11 Buys, 7 Holds and 1 Sells

Explore more price target data and ratings for Bio-Techne Corp on the , and track all previous and future analyst recommendations for Bio-Techne Corp in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Bio-Techne retention bonuses approved for Kim Kelderman, Jim Hippel](https://longbridge.com/en/news/290948213.md)
- [Bio-Techne to Be Acquired by Merck for $73 Per Share in All-Cash Merger](https://longbridge.com/en/news/290948205.md)
- [Penguin Solutions Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call](https://longbridge.com/en/news/290946532.md)
- [Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration](https://longbridge.com/en/news/290154834.md)
- [14:24 ETSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)](https://longbridge.com/en/news/290997454.md)